CEO Markus Warmuth was paid $5,032,728 in fiscal year 2025, ↑ up 106.2% from fiscal year 2024 (SEC filing 0001193125-26-191439 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,032,728 ↑ Markus Warmuth total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read Monte Rosa Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper GLUE reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
GLUE's next annual pay disclosure, estimated May 3, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Markus Warmuth | $650,000 | $0 | $910,080 | $3,043,648 | $429,000 | $0 | $0 | $5,032,728 |
| President and Chief Executive Officer | ||||||||
| Philip Nickson | 520,000 | 0 | 255,960 | 852,221 | 299,600 | 0 | 14,000 | 1,941,781 |
| Chief Business and Legal Officer | ||||||||
| Filip Janku | 520,000 | 0 | 255,960 | 852,221 | 299,600 | 0 | 14,000 | 1,941,781 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Markus Warmuth | $5,032,728 | $2,440,811 | $3,627,130 | ↑ +2,591,917 |
| Philip Nickson | 1,941,781 | 1,287,628 | — | ↑ +654,153 |
| Filip Janku | 1,941,781 | 1,257,869 | 1,486,170 | ↑ +683,912 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses GLUE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GLUE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Ali Behbahani, M.D | Independent Director | $155,186 |
| Andrew Schiff, M.D | Independent Director | $186,853 |
| Anthony Manning, Ph.D | Independent Director | $159,769 |
| Chandra P. Leo, M.D | Independent Director | — |
| Christine Siu | Independent Director | $162,686 |
| Eric Hughes, M.D., Ph.D | Independent Director | $150,603 |
| Jan Skvarka, Ph.D, MBA | Independent Director | $156,853 |
| Kimberly L. Blackwell, M.D | Independent Director | $162,686 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Markus Warmuth | RSU | 128,000 | — | $2,007,040 |
| Markus Warmuth | Option | 19,725 | 13.41 | — |
| Filip Janku | Option | 63,021 | 5.71 | — |
| Filip Janku | RSU | 36,000 | — | 564,480 |
| Philip Nickson | RSU | 36,000 | — | 564,480 |
| Markus Warmuth | Option | 127,834 | 7.78 | — |
| Markus Warmuth | Option | 180,209 | 5.71 | — |
| Markus Warmuth | Option | 575,000 | 7.11 | — |
| Filip Janku | Option | 5,407 | 13.41 | — |
| Filip Janku | Option | 36,563 | 7.78 | — |
| Filip Janku | Option | 30,000 | 7.35 | — |
| Filip Janku | Option | 161,000 | 7.11 | — |
| Philip Nickson | Option | 4,413 | 13.41 | — |
| Philip Nickson | Option | 33,489 | 7.78 | — |
| Philip Nickson | Option | 56,771 | 5.71 | — |
| Philip Nickson | Option | 24,167 | 3.98 | — |
| Philip Nickson | Option | 161,000 | 7.11 | — |
The program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors’ interests with those of our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon Hewitt Company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | — | — | — | — | — |
| 2025 | 2025-06-13 | — | — | — | — | — |
| 2024 | 2024-06-12 | — | — | — | — | — |
| 2023 | 2023-06-14 | — | — | — | — | — |
| 2022 | 2022-06-15 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | —a |
| 2025 | 2025-06-13 | —b |
| 2024 | 2024-06-12 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew Schiff, M.DIndependent · Audit · Compensation | $79,167 | $0 | $107,686 | — | $0 | $186,853 |
| Kimberly L. Blackwell, M.DIndependent · Compensation (Chair) | 55,000 | 0 | 107,686 | — | 0 | 162,686 |
| Christine SiuIndependent · Audit (Chair) | 55,000 | 0 | 107,686 | — | 0 | 162,686 |
| Anthony Manning, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 52,083 | 0 | 107,686 | — | 0 | 159,769 |
| Jan Skvarka, Ph.D, MBAIndependent · Nominating and Corporate Governance (Chair) | 49,167 | 0 | 107,686 | — | 0 | 156,853 |
| Ali Behbahani, M.DIndependent · Compensation | 47,500 | — | 107,686 | — | — | 155,186 |
| Eric Hughes, M.D., Ph.DIndependent · Nominating and Corporate Governance | 42,917 | 0 | 107,686 | — | 0 | 150,603 |
| Markus Warmuth, M.DEmployee director | — | — | — | — | — | 0 |
| Chandra P. Leo, M.DIndependent · Audit | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $380,834 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $380,834 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics | 2025 | Markus Warmuth | $650,000 | $910,080 | $3,043,648 | $429,000 | $5,032,728 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Markus Warmuth | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 5,032,728. Filing ↗machine: r2 · c25 · span 420815–420824 |
| 2 | Section 01, Philip Nickson | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 1,941,781. Filing ↗machine: r6 · c25 · span 460643–460652 |
| 3 | Section 01, Filip Janku | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 1,941,781. Filing ↗machine: r4 · c25 · span 440734–440743 |
| 4 | Section 08, Andrew Schiff, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 186,853. Filing ↗machine: span 344563–344790 |
| 5 | Section 08, Kimberly L. Blackwell, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 162,686. Filing ↗machine: span 325033–325260 |
| 6 | Section 08, Christine Siu | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 162,686. Filing ↗machine: span 349393–349620 |
| 7 | Section 08, Anthony Manning, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 159,769. Filing ↗machine: span 339727–339954 |
| 8 | Section 08, Jan Skvarka, Ph.D, MBA | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 156,853. Filing ↗machine: span 354232–354459 |
| 9 | Section 08, Ali Behbahani, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 155,186. Filing ↗machine: span 320192–320419 |
| 10 | Section 08, Eric Hughes, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 150,603. Filing ↗machine: span 329873–330100 |
| 11 | Section 08, Markus Warmuth, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Chandra P. Leo, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001193125-26-267465 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0000950170-25-086129 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 06, 2024 vote | Form 8-K | 2024-06-12 | 0000950170-24-072407 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 380,834 + equity 0 + all other 0 = 380,834, summed across the director compensation table rows.machine: formula: Σ = 380,834 |
| 18 | Monte Rosa Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191439 | CEO total compensation as printed in Monte Rosa Therapeutics's own proxy. As printed: 5,032,728. Filing ↗machine: r2 · c25 · span 420815–420824 |